Renaissance Capital logo

Kairos Pharma Priced, NYSE American: KAPA

Phase 2 biotech developing therapies for cancer.

Industry: Health Care

Latest Trade: $1.33 0.00 (0.0%)

First Day Return: -35.0%

Return from IPO: -66.9%

Industry: Health Care

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. Our mission is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. “Checkpoints” refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution.
more less
IPO Data
IPO File Date 09/29/2023
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.6
Deal Size ($mm) $6
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/16/2024
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.6
Deal Size ($mm) $6
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Boustead Securities
EF Hutton
more
Company Data
Headquarters Los Angeles, CA, United States
Founded 2013
Employees at IPO 3
Website www.kairospharma.com

Kairos Pharma (KAPA) Performance